PCSK9 Inhibition Prevents First Major Cardiovascular Events: VESALIUS‑CV trial

Highlights

– The VESALIUS‑CV global randomized trial demonstrates that evolocumab lowers the risk of first major adverse cardiovascular events (3‑point MACE reduced by 25%) among patients with atherosclerosis or diabetes but without prior myocardial infarction or stroke.

– Over a median 4.6 years, 5‑year Kaplan–Meier estimates were 6.2% vs 8.0% for 3‑point MACE (HR 0.75, 95% CI 0.65–0.86) and 13.4% vs 16.2% for 4‑point MACE (HR 0.81, 95% CI 0.73–0.89); number needed to treat (NNT) ≈56 for 3‑point MACE and ≈36 for 4‑point MACE over 5 years.